The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia
The Combination of Oral All-trans Retinoic Acid and Danazol vs Danazol as Second-line Treatment in Adult Immune Thrombocytopenia: a Multicenter, Randomized, Open-label Trial
Sponsor: Beijing Hospital
A PHASE2 clinical study on Autoimmune Thrombocytopenia, this trial is completed. The trial is conducted by Beijing Hospital and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
May 2017 — Jun 2017 [monthly]
Completed PHASE2
-
Feb 2017 — May 2017 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Hospital
- Beijing Municipal Science & Technology Commission
- Beijing Tongren Hospital
- Navy General Hospital, Beijing
- Peking University People's Hospital
- Qilu Hospital of Shandong University
For direct contact, visit the study record on ClinicalTrials.gov .